Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(1.78)
# 3,061
Out of 4,711 analysts
45
Total ratings
25%
Success rate
-3.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $4.05 | +146.91% | 1 | Dec 17, 2024 | |
| KROS Keros Therapeutics | Reiterates: Overweight | n/a | $17.03 | - | 2 | Nov 22, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $308.44 | - | 4 | Nov 20, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $8.21 | - | 5 | Sep 23, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $27.90 | +132.97% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $52.17 | - | 10 | Sep 23, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Overweight | n/a | $29.34 | - | 5 | Jun 20, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | n/a | $0.83 | - | 2 | Feb 20, 2024 | |
| TGTX TG Therapeutics | Reiterates: Overweight | $24 | $32.20 | -25.47% | 2 | Apr 17, 2023 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $1.96 | +22,859.18% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.61 | +2,202.63% | 1 | Mar 3, 2021 |
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.05
Upside: +146.91%
Keros Therapeutics
Nov 22, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.03
Upside: -
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $308.44
Upside: -
ORIC Pharmaceuticals
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.21
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $27.90
Upside: +132.97%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $52.17
Upside: -
Akero Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.34
Upside: -
RAPT Therapeutics
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.83
Upside: -
TG Therapeutics
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $32.20
Upside: -25.47%
Alaunos Therapeutics
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $1.96
Upside: +22,859.18%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.61
Upside: +2,202.63%